Details of the Drug Combinations

General Information of This Drug (ID: DM5QF9V)

• Drug Name: Tamsulosin (DM5QF9V)
• Synonyms: Flomax; Flowmax; Harnal; Tamsolusin; Tamsulon; Tamsulosina; Tamsulosine; Tamsulosinum; Flomax (TN); Flomaxtra (TN); Tamsulon (TN); Tamsulosin (INN); Tamsulosin [INN:BAN]; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; Tamsulosinum [INN-Latin]; Urimax (TN); (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide

Indication

Benign prostatic hyperplasia; ICD 11: GA90; Status: Approved [1]; Urinary retention; ICD 11: MF50.3; Status: Approved [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Tamsulosin + Dutasteride	DCA9CVA	Dutasteride	Prostatic Hyperplasia	[3]
Tamsulosin + Tolterodine	DCE81VD	Tolterodine	Prostatitis	[4]
Tamsulosin + Finasteride	DCMM90O	Finasteride	Benign Prostatic Hyperplasia	[5]
Tamsulosin + Mirabegron	DCRN6VE	Mirabegron	Cardiovascular	[6]
Tamsulosin + Finasteride	DCRY36V	Finasteride	Benign Prostate Hyperplasia	[7]
Tamsulosin + Solifenacin	DCKLHEQ	Solifenacin	LUTS	[8]
Tamsulosin + Tadalafil	DCZFES9	Tadalafil	Healty Male Volunteers	[9]
Tamsulosin + Mirabegron	DCY82ZV	Mirabegron	Nephrolithiasis	[10]
Tamsulosin + Solifenacin	DCDHYLX	Solifenacin	Lower Urinary Tract Symptoms	[11]
Tamsulosin + Mirabegron	DCWAMR7	Mirabegron	Overactive Bladder	[12]
Tamsulosin + Diclofenac	DCX0L9Q	Diclofenac	Renal Stone	[13]
Tamsulosin + Acetaminophen	DCYT2BO	Acetaminophen	Nephrolithiasis	[10]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 488).
• [2] Tamsulosin FDA Label
• [3] ClinicalTrials.gov (NCT01657851) Bioequivalence - Duodart Against Avodart & Omnic
• [4] ClinicalTrials.gov (NCT00913315) Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis
• [5] ClinicalTrials.gov (NCT01534351) Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
• [6] ClinicalTrials.gov (NCT01489696) A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
• [7] ClinicalTrials.gov (NCT01736033) Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients
• [8] ClinicalTrials.gov (NCT02180997) Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
• [9] ClinicalTrials.gov (NCT02247505) CKD-397 Drug-drug Interaction Study (B)
• [10] ClinicalTrials.gov (NCT02095665) Ureteral Stent-related Pain and Mirabegron (SPAM) Trial
• [11] ClinicalTrials.gov (NCT02715024) Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
• [12] ClinicalTrials.gov (NCT02656173) A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
• [13] ClinicalTrials.gov (NCT04819828) Tamsulosin as Adjunctive Therapy After Extracorporeal Shock Wave Lithotripsy for Renal Stones